Forum Topic News
  • Conversation: PharmaVentures Capital Limited Advises Biosceptre International Limited, a Clinical Stage Oncology Company, on its Series A Private Placement by Tuspark S&T

    • December 15, 2017 12:42 PM GMT
      • Post(s)
        548

      PharmaVentures Capital Limited Advises Biosceptre International Limited, a Clinical Stage Oncology Company, on its Series A Priv...

      OXFORD, England, December 15, 2017 /PRNewswire/ --
      PharmaVentures Capital Limited is pleased to announce that it acted as adviser to Biosceptre International Limited ("Biosceptre") for the successful Series A private placement from the Chinese conglomerate Tuspark Science & Technology Service Group (Tuspark) through its investment vehicle, Bluesky Partnership II L.P. As Tuspark's first major overseas investment into biotech, this represents a strong belief in the Biosceptre team and the potential transformative effects their therapies may bring to cancer patients.
      Biosceptre's therapies are focused upon a novel cancer target, nfP2X7, that is completely absent in healthy tissue, but present on tumour tissue in the majority of cancers, including lung, breast, colorectal and prostate. For more information on Biosceptre's therapies see http://www.biosceptre.com/pipeline/.
      This first institutional raise will allow Biosceptre to advance its three oncology clinical assets which are BIL010t, a polyclonal antibody ointment for the topical treatment of non-melanoma skin cancers, BIL06v, a peptide protein conjugate and BIL03s, fully human domain monoclonal, both for systemic uses targeting solid and blood cancers. Clinical trials are being planned in Australia, UK and EU.
      Fintan Walton, Chairman and Chief Executive of PharmaVentures, said: "This investment by the Chinese company Tuspark S&T in Biosceptre represents a significant landmark for both the UK Biotechnology sector and PharmaVentures Capital Limited."
      Adrian Dawkes, Managing Director at PharmaVentures, added; "As a long-standing client, PharmaVentures is pleased to have advised Biosceptre on this transaction. We are delighted to have been able to leverage our relationships in China to secure this investment for the company."
      For the past 25 years, PharmaVentures has acted as an advisor to over 700 global pharmaceutical and biotechnology clients in transactions; many covering licensing, mergers, acquisitions, divestments and joint venture activities for companies.
      Read more: http://bit.ly/PharmaventuresBiosceptre

Add Reputation

Do you want to add reputation for this member by this post?

or cancel
‚Äč